ZELAPAR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zelapar, and what generic alternatives are available?
Zelapar is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in ZELAPAR is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zelapar
A generic version of ZELAPAR was approved as selegiline hydrochloride by I3 PHARMS on April 1st, 1997.
Summary for ZELAPAR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 97 |
Clinical Trials: | 3 |
Patent Applications: | 4,553 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ZELAPAR |
What excipients (inactive ingredients) are in ZELAPAR? | ZELAPAR excipients list |
DailyMed Link: | ZELAPAR at DailyMed |
Recent Clinical Trials for ZELAPAR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of South Florida | Phase 4 |
Valeant Pharmaceuticals International, Inc. | Phase 4 |
Bausch Health Americas, Inc. | Phase 4 |
Pharmacology for ZELAPAR
Drug Class | Monoamine Oxidase Inhibitor Monoamine Oxidase Type B Inhibitor |
Mechanism of Action | Monoamine Oxidase Inhibitors Monoamine Oxidase-B Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ZELAPAR
US Patents and Regulatory Information for ZELAPAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | ZELAPAR | selegiline hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021479-001 | Jun 14, 2006 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZELAPAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch | ZELAPAR | selegiline hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021479-001 | Jun 14, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
Bausch | ZELAPAR | selegiline hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021479-001 | Jun 14, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZELAPAR
See the table below for patents covering ZELAPAR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 69614096 | ⤷ Try a Trial | |
United Kingdom | 9504201 | ⤷ Try a Trial | |
New Zealand | 252526 | SOLID DOSAGE FORM CONTAINING ONE OR MORE AMINO ACIDS IN A MATRIX MATERIAL COMPRISING GELATIN, PECTIN, AND/OR SOY FIBRE PROTEIN AND WHICH DISPERSES RAPIDLY IN WATER | ⤷ Try a Trial |
Japan | 2969002 | ⤷ Try a Trial | |
Ireland | 904520 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |